Günter Eisele

TL;DR: RNA interference targeting TGF-β1,2 results in a glioma cell phenotype that is more sensitive to immune cell lysis and less motile in vitro and nontumorigenic in nude mice, strongly confirming TGF -β antagonism as a major therapeutic strategy for the future treatment of malignant gliomas.

TL;DR: Escape from NKG2D-mediated immune surveillance of malignant gliomas in vivo may be promoted by the inhibition of MICA and ULBP2 expression via an autocrine TGF-β loop and by MP-dependent shedding from the cell surface.

TL;DR: In this paper, the authors investigated whether a blood-derived specific miRNA fingerprint can be defined in patients with glioblastoma using machine learning and obtained a comprehensive miRNA signature with an accuracy of 81% [95% confidence interval (CI) 78-84%], specificity of 79% (95% CI 75-83%) and sensitivity of 83% ( 95% CI 71-85%).

TL;DR: The alterations affecting the p53 pathway, the BCL-2 protein family, the inhibitor of apoptosis proteins and several growth factor pathways involved in the regulation of programmed cell death are described and possible targets for new therapies within these apoptotic pathways in glioblastomas are defined.

TL;DR: Analysis of patterns of progression on MRI in 21 patients enrolled onto a phase 2 trial of cilengitide added to TMZ/RT → TMZ in newly diagnosed glioblastoma provides no evidence for an anti-invasive activity of cILENGitide in patients with newly diagnosed GliOBlastoma.